Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Sharp L, Foll P, Deady S, O'Ceilleachair A, Buicke C, Carsin AE. Where do people with lung cancer die and how is this changing? A population-based study. Irish Med J. 2010 Oct;103(9):262-6.
Pladevall M, Arana A, Varas-Lorenzo C. Systematic reviews and meta-analyses in ischemic cardiopathy. Cardiovasc Risk Fact. 2000;4:270-81.
Pladevall-Vila M, Arana A, Varas-Lorenzo C. Systematic reviews and meta-analysis on coronary heart disease. (Revisiones sistemáticas y meta-análisis en cardiopatía isquemica). Cardiovasc Risk Fact. 2000;4:270-81.